The Effect of Hepatectomy on the Synthesis of 25-Hydroxyvitamin D₃

E. B. OLSON, JR., J. C. KNUTSON, M. H. BHATTACHARYYA, and
H. F. DeLUCA

*From the Department of Biochemistry, College of Agricultural and Life
Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53706*

ABSTRACT The metabolism of [³H]vitamin D₃ in hepatectomized vitamin D-deficient rats has been studied. Hepatectomy drastically disrupts vitamin D₃ metabolism as revealed by prolonged high levels of [³H]vitamin D₃ in the plasma compartment even 12 h after dose in contrast to sham-operated controls. Some conversion of [³H]vitamin D₃ to [³H]25-hydroxyvitamin D₃ was detected in hepatectomized rats, but the amount was small in spite of the high circulating levels of [³H]vitamin D₃. Since the liver initially takes up much of an administered dose in normal animals and the conversion of [³H]vitamin D₃ to [³H]25-hydroxyvitamin D₃ is small in hepatectomized rats in spite of high circulating [³H]-vitamin D₃, it is concluded that the liver plays a major role in the metabolism of vitamin D₃ to 25-hydroxyvitamin D₃.

INTRODUCTION

The metabolic processes and chemical alterations necessary for vitamin D to fulfill its role in regulating calcium homeostasis have been clarified dramatically by a series of discoveries made within the past decade. Several recent reviews serve as excellent sources for those interested in a complete discussion of vitamin D metabolism and mechanism of action (1-3).

Under normal circumstances, only small amounts of unchanged vitamin D circulate in the bloodstream. Unneeded vitamin D appears to be either stored as the unchanged molecule in adipose tissue (4) or metabolized and excreted. Vitamin D needed to fulfill its physiologi-

cal roles must first undergo chemical alteration. The initial, obligatory step in vitamin D metabolism is hydroxylation at carbon-25 on the side chain.

Normally, the majority of circulating vitamin D is initially taken up by the liver where it can be converted to 25-hydroxyvitamin D₃ (25-OH-D₃).¹ Fig. 1 is a summary of data from several sources (5-8); it graphically illustrates the time sequence of the metabolic pools of vitamin D₃ in the liver and plasma of vitamin D-deficient rats after a single intravenous dose of radioactive vitamin D₃. The initial rapid disappearance of ³H from plasma corresponds with a large uptake of radioactivity by the liver. At approximately 2-4 h, the disappearance of [³H]plasma is interrupted by a rebound in radioactivity which is associated with a drop in liver radioactivity. This rebound can be accounted for by the appearance of 25-OH-D₃ in the plasma compartment.

Based on such data, Ponchon and DeLuca first postulated that the liver is the major site of vitamin D₃ conversion to 25-OH-D₃ (5). Later, they showed that the isolation of the liver from the circulation of vitamin D-deficient rats almost completely eliminates their ability to produce 25-OH-D₃ (6). However, the possibility of some liver participation in the production of the small amount of 25-OH-D₃ found in the plasma could not be excluded, since the vascularly isolated livers were still able to accumulate approximately 10% of the [³H]vitamin D₃ by 4 h.

Subsequent *in vivo* and *in vitro* studies of the liver hydroxylase responsible for the formation of 25-OH-D₃ (9-11) have strengthened the idea that the liver is the major, if not sole, site of 25-OH-D₃ production, and through this function serves as the obligatory source of the precursor for production of metabolically active 1,25-dihydroxyvitamin D₃ (1,25-[OH]₂D₃).

Dr. Olson's present address is Department of Preventive Medicine, University of Wisconsin-Madison, Madison, Wis. 53705; Dr. Knutson's is Department of Biochemistry, University of Washington, Seattle, Wash. 98195; and Dr. Bhattacharyya's is Argonne National Laboratories, Argonne, Ill. 60439.

Received for publication 30 October 1975 and in revised form 12 January 1976.

¹ Abbreviations used in this paper: 25-OH-D₃, 25-hydroxyvitamin D₃; 1,25-(OH)₂D₃, 1,25-dihydroxyvitamin D₃.

FIGURE 1 Liver and plasma radioactivity after an intrajugular injection of 10 IU (650 pmol) of $[1,2-^3\text{H}]$ vitamin D_3 into vitamin D-deficient rats. These profiles are composites of data from several sources (5–8). The time-courses were smoothed through the use of weighted averages including values observed in successive 40-min intervals. The plasma tritium was chromatographed and the fraction of the dose corresponding to unchanged vitamin D_3 , 25-OH- D_3 , or other metabolites of vitamin D_3 is indicated.

Recently the uniqueness of the liver's role in the 25-hydroxylation of vitamin D has been challenged. Using the chick as a model for vitamin D metabolism, Tucker et al. (12) demonstrated that significant conversion of vitamin D_3 to 25-OH- D_3 occurs in homogenates from chick intestine and kidney as well as from chick liver. This would appear to conflict with the *in vivo* experiments of Ponchon et al. (6) which used hepatectomized rats. Assuming that the demonstration of 25-hydroxylation by intestine and kidney *in vitro* is correct, there remains the question of whether such conversion occurs *in vivo*. Although the experiments of Ponchon et al. (6) showed essentially no 25-hydroxylation by hepatectomized rats, these animals survived for only a 4-h period. Recently, Bollman and Van Hook have developed a technique for completely excising the liver from a living rat without compromising the intestinal venous drainage (13), which permitted much

longer survival of rats. Using this technique, it has been possible to demonstrate that hepatectomized rats can convert vitamin D_3 to 25-OH- D_3 . However, the amount is small and occurs in the face of high circulating levels of vitamin D_3 . Additionally, hepatectomy greatly alters the course of vitamin D metabolism.

METHODS

20-day-old male Holtzman rats were fed a purified vitamin D-deficient diet (0.47% calcium, 0.3% phosphorus) supplemented with fat-soluble vitamins A, E, and K (14). After 1 wk these rats weighed approximately 75 g and were used for the two-stage hepatectomy developed by Bollman and Van Hook (13). The first stage of this operation consists of ligating the inferior vena cava just proximal to the right renal vein and placing a cellophane band loosely around the portal vein. (A band of approximately 2-mm width was subjectively observed to produce less adhesions between the liver and duodenum than the originally recommended 5-mm width band.) All experimental animals, including the sham-operated controls, underwent the first stage of the operation.

Over 45% (42 of 93) of these young rats recovered from surgery and survived on the vitamin D-deficient diet for an additional 6–8 wk. By this time these rats were deficient in vitamin D, as evidenced by a lack of growth and low serum calcium levels, and their portal veins had become completely occluded with the development of sufficient collateral circulation to permit the second stage of the hepatectomy operation (13). All animals were fasted for 12 h; for certain experiments, a number of the animals were given a 0.25- μg (10 IU) dose of vitamin D_3 (gift of the Philips-Duphar Company of Amsterdam, The Netherlands) intrajugularly under light ether anesthesia 9 h before the second stage of the operation. Sham-operated controls were subjected to the same manipulations as required for removing the liver, except the sutures were placed and withdrawn without ligating vessels.

After the abdominal incision was closed, all experimental animals received an intrajugular dose of $[^3\text{H}]$ vitamin D_3 . (The $[1,2-^3\text{H}]$ vitamin D_3 used [sp act 1,262 dpm/pmol] was prepared according to the method of Neville and DeLuca [15].) The rats were then allowed to recover from the ether anesthesia and were maintained by frequent glucose administration. The tail vein cannulation recommended by Bollman and Van Hook (13) was not used; instead, all the rats (experimental and sham operated) were given an initial 2.5-ml intraperitoneal injection of 10% glucose followed by 1.0-ml hourly injections. This regimen of glucose administration was adequate for maintaining the hepatectomized rats for up to a 12-h experimental period. Those rats that failed to survive for the entire experimental period died due to bleeding or complications, which at autopsy could be directly related to surgical technique and not to hypoglycemia. The percentage of hepatectomy survivors steadily increased as the required surgical procedures were mastered.

At the end of the maintenance period the experimental rats were sacrificed by decapitation. The exposed blood vessels were heparinized and as much blood as possible was collected in a heparinized centrifuge tube. As indicated, appropriate organs were dissected out and stored frozen at -20°C until used for analysis. Tissue lipids were extracted using the modified Bligh and Dyer (16) method described by Lund and DeLuca (17). An aliquot of the extract was counted and the remainder was dissolved in 65:35 chloroform-Skellysolve B (Skelly Oil Co., Kansas City, Mo.) and

applied to a glass column (1×60 cm) containing 15 g of Sephadex LH-20 according to the procedure of Holick and DeLuca (18). An aliquot from each fraction collected from these columns was dried in 15×45-mm glass vial inserts with a stream of air, dissolved in 4 ml of toluene counting solution (2 g of PPO and 0.1 g of POPOP per 1 liter of toluene), and counted in a Packard Tri-Carb model 3375 liquid scintillation counter (Packard Instrument Co., Inc., Downers Grove, Ill.). In some cases the fractions collected in the 25-OH-D₃ region of the LH-20 profile were pooled and subjected to co-chromatography with [26,27-¹⁴C]25-OH-D₃ (synthesized in this laboratory by M. F. Holick) on hydroxyalkoxypropyl Sephadex as described by Jones et al. (19). The hydroxyalkoxypropyl Sephadex used had a 55% hydroxyalkyl group content and was prepared in this laboratory by G. Jones using Nedox 1518 (a gift from Ashland Chemical Co., Columbus, Ohio), according to the method described by Ellingboe et al. (20). Total disintegrations of ³H (and ¹⁴C where applicable) were determined through routine use of an automatic external standard and a computer program correcting for efficiency, channel spillover, and background radiation. Plasma extract results are expressed as the percent of the original [³H]vitamin D₃ dose, assuming that plasma comprises 3.0% of the total body weight. In all cases, hematocrits of experimental and control animals remained within normal limits.

RESULTS

Using the described protocol we achieved approximately 30% (26/88) success in producing hepatectomized vitamin D-deficient rats. 54% (14/26) of these rats recovered and survived without a liver until sacrificed 4, 6, or 12 h later. In addition, five vitamin D-deficient rats,

which had recovered from the first stage of the operation, were used as sham-operated controls. Four of these survived until sacrificed.

6 h after hepatectomized rats received an intrajugular dose of 10 IU (650 pmol) [³H]vitamin D₃, approximately 50% of the ³H remained in the plasma compartment. A composite profile of the Sephadex LH-20 chromatography of the plasma extract is shown in Fig. 2B. 1.4% of the administered radioactivity chromatographed in the same region as 25-OH-D₃, and 49.1% chromatographed in the same region as unchanged vitamin D₃.

The fact that over 50% of the initial vitamin D₃ dose is in the plasma compartment of hepatectomized rats after 6 h indicates that the rat without a liver does not remove vitamin D₃ from its blood very efficiently. An overview of the overall disappearance of a 10-IU intravenous dose of vitamin D₃ in vitamin D-deficient rats without a liver is shown in Fig. 2. The Sephadex LH-20 profile of the plasma extract from a hepatectomized rat 6 h after an intrajugular dose of 10-IU vitamin D₃ (Fig. 2B) is compared with the profiles 4 and 12 h after a similar dose. Notice that at 12 h (Fig. 2C) over 30% of the original radioactivity remains in the plasma in a peak which chromatographs in the same region as unchanged vitamin D₃, while 1.5% of the original radioactivity in the plasma chromatographs similarly to 25-OH-D₃. After 4 h (Fig. 2A), approximately 80% of the

FIGURE 2 Sephadex LH-20 chromatographic profiles of tritium extracted from the plasma of vitamin D-deficient rats at different times after hepatectomy and an intrajugular dose of 10 IU (650 pmol) of [1,2-³H]vitamin D₃. (2A, A composite of data from three rats; 2B, two columns, one rat and a pool of two rats; 2C, data from a single rat.)

administered vitamin D₃ remains in the plasma compartment of hepatectomized, vitamin D-deficient rats. The great majority of this plasma radioactivity appears to be unchanged vitamin D₃. Approximately 0.5% of the original 10 IU (650 pmol) of vitamin D₃ has been converted to a 25-OH-D₃-like metabolite.

Because in the previous experiment the tissues were exposed to high concentrations of [³H]vitamin D₃ for long periods, the dose of [³H]vitamin D₃ to hepatectomized rats was reduced to 6.5 IU. Table I presents a comparison of the data obtained with sham-operated rats and hepatectomized rats 6 h after the indicated dose of [³H]vitamin D₃. The percentage of the dose circulating as vitamin D₃ is not changed by reducing the dose of [³H]vitamin D₃ from 10 to 6.5 IU. Thus, the actual amount of circulating vitamin D₃ is reduced from 319.2 to 185.5 pmol simply by reducing the dose of vitamin D₃ from 10 to 6.5 IU. However, this reduced level of circulating vitamin D₃ is still over twice the level of vitamin D₃ circulating in intact rats at 6 h after dose.

Interestingly, the reduction in the amount of circulating vitamin D₃ achieved by reducing the initial vitamin D₃ dose does reduce the amount of circulating 25-OH-D₃-like material. 6 h after injecting 6.5 IU of [³H]-vitamin D₃ into hepatectomized rats, 0.9% of the dose or 3.8 pmol is circulating as a 25-OH-D₃-like metabolite. In contrast, the 10-IU dose produces a 25-OH-D₃ peak which contains 9.1 pmol or 1.4% of the original dose.

The effects of removing the liver on vitamin D metabolite accumulation by kidney and small intestine com-

pared to the plasma metabolites are shown in Table II. 6 h after a 10-IU intrajugular dose of [³H]vitamin D₃, a sham-operated rat had 4.6% of the dose circulating in the plasma as 25-OH-D₃-like material and 0.4% of the dose as 1,25-(OH)₂D₃-like material. In the same rat, the kidneys and small intestine had also accumulated significant amounts of unchanged vitamin D₃, 25-OH-D₃, and 1,25-(OH)₂D₃-like material. In contrast to this, a hepatectomized rat which has an elevated circulating level of unchanged vitamin D₃ and a small amount of circulating 25-OH-D₃-like material had no detectable 1,25-(OH)₂D₃ in its plasma, kidneys, or small intestine and very reduced levels of 25-OH-D₃-like material in its kidney or small intestine compared to the sham-operated control. Interestingly, the hepatectomized rat did accumulate unchanged vitamin D₃ in its kidneys and small intestine.

The previous results (Fig. 2 and Tables I and II) indicate that in hepatectomized rats the normal sequence of vitamin D₃ metabolism is dramatically altered. In Fig. 3 the chromatographic profiles of plasma lipid extracts from sham-operated controls which had survived the alterations in visceral circulation produced by the first stage of the hepatectomy operations are illustrated. Both 6 and 12 h after an intrajugular dose of 10 IU ³H-vitamin D₃, the vitamin D-deficient rats which retained their livers (with a somewhat altered circulation) were able to approximate the normal vitamin D₃ plasma metabolic pattern as summarized in Fig. 1. These rats clearly exhibited a more rapid reduction in circulating vitamin D₃ and a greater production of 25-

TABLE I
25-OH-D₃ Production at Varying Vitamin D₃ Levels

	Dose				D ₃ /25-OH-D ₃
	Vitamin D ₃ peak		25-OH-D ₃ peak		
	%	<i>pmol</i>	%	<i>pmol</i>	
Sham, 10 IU [³ H]D ₃	14.2 (8.8–19.6)*	92.3	3.9 (3.2–4.6)	25.4	3.6 (2.8–4.2)
Hepatectomy, 10 IU [³ H]D ₃	49.1 (39.9–57.8)	319.2	1.4 (1.4–1.4)	9.1	35.1 (29.3–39.9)
Hepatectomy, 6.5 IU [³ H]D ₃	43.9 (37.5–50.4)	185.5	0.9 (0.8–1.1)	3.8	48.8 (46.6–49.4)

Unchanged vitamin D₃ and 25-OH-D₃ Sephadex LH-20 peaks from the plasma of vitamin D-deficient rats with or without their livers 6 h after the indicated intrajugular dose of [1,2-³H] vitamin D₃. (Sham, composite of data from two rats; hepatectomy, composite of data from three rats; 6.5 IU hepatectomy, composite of data from four rats).

* Values in parentheses, range.

TABLE II
Accumulation of 25-OH-D₃ and 1,25-(OH)₂D₃ in Tissues of Hepatectomized Rats

	Dose			
	Recovered	Vitamin D ₃ peak	25-OH-D ₃ peak	1,25-(OH) ₂ D ₃ peak
	%	%	%	%
Sham				
Plasma	29.9	19.5	4.6	0.4
Kidneys	10.9	8.4	0.6	0.02
Small intestine	9.6	1.5	0.4	0.08
Hepatectomized				
Plasma	44.8	40.2	1.4	—*
Kidneys	4.6	3.4	0.10	—*
Small intestine	6.6	4.8	0.06	—*

Analysis of the indicated tissue compartments from two vitamin D-deficient rats with or without their livers 6 h after a 10-U (650 pmol) intrajugular dose of [1,2-³H]vitamin D₃.

* Undetectable.

FIGURE 3 Sephadex LH-20 chromatographic profiles of tritium extracted from the plasma of vitamin D-deficient rats 6 or 12 h after a sham hepatectomy and an intrajugular dose of 10 IU (650 pmol) of [1,2-³H]vitamin D₃. (3A, A composite of data from two rats; 3B, data from a single rat.)

FIGURE 4 Sephadex LH-20 chromatographic profiles of tritium extracted from the plasma of vitamin D-deficient rats 6 h after the indicated liver operation and an intrajugular dose of 10 IU (650 pmol) of $[1,2-^3\text{H}]$ vitamin D_3 . The rats were given an intrajugular dose of 10 IU (650 pmol) of nonradioactive vitamin D_3 9 h before surgery. (4A, data from a single rat; 4B, a composite of data from two rats.)

OH- D_3 -like material than the corresponding hepatectomized rats (Fig. 2B and C).

Vitamin D-deficient rats do appear to be able to produce a 25-OH- D_3 -like metabolite in the absence of their livers. Fig. 4 presents data which indicate that the production of a 25-OH- D_3 -like metabolite in hepatectomized rats is inhibited by a 10-IU predose of unlabeled vitamin D_3 (compare Fig. 4B with Fig. 2B) just as it does to intact vitamin D-deficient animals (compare Fig. 4A with Fig. 3A). Thus, the 25-OH- D_3 -like material produced by rats without a liver appears to be subject to feedback inhibition analogous to the previously studied hepatic vitamin D_3 -25-hydroxylase system (10, 11).

The vitamin D_3 metabolite extracted from hepatectomized rat plasma which chromatographs like 25-OH- D_3 on Sephadex LH-20 in part co-chromatographs with synthetically prepared ^{14}C -labeled 25-OH- D_3 on a hy-

droxyalkoxypropyl Sephadex chromatographic system. Fig. 5 is a composite representative of two instances in which the tritium containing 25-OH- D_3 metabolite, isolated after Sephadex LH-20 chromatography of hepatectomized rat plasma lipid extract, was combined with synthetically prepared ^{14}C -labeled 25-OH- D_3 . Notice that over 84% of the ^{14}C -labeled 25-OH- D_3 was recovered in a symmetrical 25-OH- D_3 peak. Approximately 58% of the tritium-containing metabolite obtained from Sephadex LH-20 chromatography co-chromatographs precisely with the known ^{14}C -labeled 25-OH- D_3 peak. The remainder of the tritium was found in small amounts in the remaining fractions.

DISCUSSION

It is apparent that extrahepatic 25-hydroxylation of vitamin D_3 is possible, inasmuch as totally hepatectomized rats produce a metabolite from vitamin D_3 which co-

chromatographs with [^{14}C]25-OH- D_3 on a column which has powerful resolving ability (19). However, the amount of 25-OH- D_3 produced in hepatectomized rats is small in spite of high circulating levels of [^3H]vitamin D_3 . Reduction of the dose of [^3H]vitamin D_3 to the limit dictated by the specific activity of [^3H]vitamin D_3 reduced the amount of [^3H]25-OH- D_3 appearing in the serum of hepatectomized rats. However, the circulating levels of [^3H]vitamin D_3 in this experiment were still very high relative to those in intact rats. Furthermore, almost half of the ^3H material which migrated as 25-OH- D_3 on Sephadex LH-20 chromatography of the extracts from hepatectomized rats did not co-chromatograph with 25-OH- D_3 . This column, on the other hand, gave 85% recovery of standard [^{14}C]25-OH- D_3 , demonstrating that a significant amount of the 25-OH- D_3 -like material from hepatectomized rats is not 25-OH- D_3 . Because the actual amount of [^3H]25-OH- D_3 in serum which is derived from [^3H]vitamin D_3 in hepatectomy is very small even in the face of high circulating amounts of [^3H]vitamin D_3 , we concluded that in the rat, extrahepatic production of 25-OH- D_3 under physiological conditions is likely very small. This view is also supported by the fact that the liver initially accumulates much of the administered dose of vitamin D_3 and that the vitamin D_3 does not proceed to the extrahepatic tissues until 25-OH- D_3 appears in the blood (5–8, 15). Thus, physiologically, the route of vitamin D metabolism must initially involve the liver.

That the liver plays an important role in vitamin D metabolism is strongly supported by the present results. In the absence of the liver vitamin D_3 persists for a long period of time in the vascular compartment. This contrasts with the rapid disappearance of vitamin D_3 from the plasma compartment in intact rats (5–8). It is not clear why adipose and other tissues do not rapidly take up the vitamin D_3 from the circulation in the absence of liver. It is possible that the liver plays an important role in the biogenesis of a transport protein of plasma which may play a role in tissue uptake. Another possibility is that the liver may play an important role in the association of vitamin D with the transport protein (21). Still another possibility is an enterohepatic circulation system (22). These possibilities all merit further investigation.

In the present study the possible appearance of 25-OH- D_3 in small intestine and kidney was also examined. In the intact animal the expected pattern of 25-hydroxylation in the liver followed by 1-hydroxylation in the kidney is reflected in the appearance of circulating metabolites corresponding to 25-OH- D_3 and 1,25-(OH) $_2\text{D}_3$ and the accumulation of these metabolites in target tissues. However, in the hepatectomized rat, even though there does appear to be a small amount of circulating

FIGURE 5 Co-chromatography of suspected [^3H]25-OH- D_3 with [^{14}C]25-OH- D_3 on hydroxyalkoxypropyl Sephadex columns. Vitamin D -deficient rats were hepatectomized and given an intrajugular dose of either 10 IU (650 pmol) or 6.5 IU (422.5 pmol) of [1,2- ^3H]vitamin D_3 . The tritium from the 25-OH- D_3 region of the Sephadex LH-20 chromatographic profiles of the plasma extracted after 6 h was mixed with approximately the same number of counts of [^{14}C]25-OH- D_3 and co-chromatographed.

25-OH- D_3 -like material, an even smaller portion of this material is accumulated in the kidney and small intestine, and no 1,25-(OH) $_2\text{D}_3$ -like material could be detected in any of the tissue extracts. Thus, any extrahepatic 25-OH- D_3 made in these rats would appear to be of limited functional importance, inasmuch as 25-OH- D_3 must be converted to 1,25-(OH) $_2\text{D}_3$ in the kidney before it can fulfill its physiological roles.

The rather unhealthy condition of hepatectomized rats may draw the criticism that this condition may inhibit extrahepatic 25-hydroxylation. This criticism is difficult to avert by any feasible technique. However, in support of the hepatectomy experiments, little or no *in vitro* 25-hydroxylation of vitamin D_3 by intestine and kidney (9, 23) has been observed in rats (12, 23). Fur-

thermore, the hepatectomized rats survived for 12 h, and it would appear that at least during the first few hours when significant 25-hydroxylation should have occurred, the health criticism should be less valid.

The nature of the extrahepatic 25-hydroxylation is unknown. Since it is apparently inhibited by a predose of vitamin D₃, it would appear to be similar to the hepatic microsomal 25-hydroxylation (11). However, at least some of it may be carried out by the same system which hydroxylates cholesterol and dihydrotachysterol (24).

Unfortunately, the precise physiological significance of the extrahepatic 25-hydroxylation cannot be firmly ascertained. The present study, however, strongly supports the major importance of the liver in the metabolism of vitamin D₃ in general and 25-hydroxylation in particular at least in mammals.

ACKNOWLEDGMENTS

This work was supported by a grant from the National Institutes of Health No. AM-14881 and the Wisconsin Alumni Research Foundation.

REFERENCES

- DeLuca, H. F. 1974. Vitamin D: the vitamin and the hormone. *Fed. Proc.* **33**: 2211-2219.
- Kodicek, E. 1974. The story of vitamin D from vitamin to hormone. *Lancet*. **I**: 325-329.
- Olson, E. B., Jr., and H. F. DeLuca. 1973. Vitamin D: metabolism and mechanism of action. *World Rev. Nutr. Diet.* **17**: 164-188.
- Rosenstreich, S. J., C. Rich, and W. Volwiler. 1971. Deposition in and release of vitamin D₃ from body fat: evidence for a storage site in the rat. *J. Clin. Invest.* **50**: 679-687.
- Ponchon, G., and H. F. DeLuca. 1969. The role of the liver in the metabolism of vitamin D. *J. Clin. Invest.* **48**: 1273-1279.
- Ponchon, G., A. L. Kennan, and H. F. DeLuca. 1969. "Activation" of vitamin D by the liver. *J. Clin. Invest.* **48**: 2032-2037.
- Ponchon, G., and H. F. DeLuca. 1969. Metabolites of vitamin D₃ and their biological activity. *J. Nutr.* **99**: 157-167.
- DeLuca, H. F. 1969. 25-Hydroxycholecalciferol. The probable metabolically active form of vitamin D₃: its identification and subcellular site of action. *Arch. Intern. Med.* **124**: 442-450.
- Horsting, M., and H. F. DeLuca. 1969. *In vitro* production of 25-hydroxycholecalciferol. *Biochem. Biophys. Res. Commun.* **36**: 251-256.
- Horsting, M., and H. F. DeLuca. 1970. Feed-back control of 25-hydroxycholecalciferol production. *Fed. Proc.* **29**: 542. (Abstr.)
- Bhattacharyya, M. H., and H. F. DeLuca. 1973. The regulation of rat liver calciferol-25-hydroxylase. *J. Biol. Chem.* **248**: 2969-2973.
- Tucker, G., III, R. E. Gagnon, and M. R. Haussler. 1973. Vitamin D₃-25-hydroxylase: tissue occurrence and apparent lack of regulation. *Arch. Biochem. Biophys.* **155**: 47-57.
- Bollman, J. L., and E. Van Hook. 1968. A simplified two-stage hepatectomy in the rat. *J. Appl. Physiol.* **24**: 722-723.
- Suda, T., H. F. DeLuca, and Y. Tanaka. 1970. Biological activity of 25-hydroxyergocalciferol in rats. *J. Nutr.* **100**: 1049-1052.
- Neville, P. F., and H. F. DeLuca. 1966. The synthesis of [1,2-³H] vitamin D₃ and the tissue localization of a 0.25 µg (10 IU) dose per rat. *Biochemistry*. **5**: 2201-2207.
- Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* **37**: 911-917.
- Lund, J., and H. F. DeLuca. 1966. Biologically active metabolite of vitamin D₃ from bone, liver, and blood serum. *J. Lipid Res.* **7**: 739-744.
- Holick, M. F., and H. F. DeLuca. 1971. A new chromatographic system for vitamin D₃ and its metabolites: resolution of a new vitamin D₃ metabolite. *J. Lipid Res.* **12**: 460-465.
- Jones, G., H. K. Schnoes, and H. F. DeLuca. 1975. Isolation and identification of 1,25-dihydroxyvitamin D₃. *Biochemistry*. **14**: 1250-1256.
- Ellingboe, J., E. Nyström, and J. Sjövall. 1970. Liquid-gel chromatography on lipophilic-hydrophobic Sephadex derivatives. *J. Lipid Res.* **11**: 266-273.
- Rikkers, H., and H. F. DeLuca. 1967. An *in vivo* study of the carrier proteins of ³H-vitamin D₃ and D₄ in rat serum. *Am. J. Physiol.* **213**: 380-386.
- Arnaud, S. B., R. S. Goldsmith, P. W. Lambert, and V. L. W. Go. 1975. 25-Hydroxyvitamin D₃: evidence of an enterohepatic circulation in man. *Proc. Soc. Exp. Biol. Med.* **149**: 570-572.
- DeLuca, H. F., S. A. Holick, and M. F. Holick. 1976. The metabolism and function of 1α-hydroxyvitamin D₃. In *Calcified Tissue 1975*. S. Pors Nielsen and E. Højort-Hansen, editors. F.A.D.L. Publishing Company, Copenhagen. In press.
- Bhattacharyya, M. H., and H. F. DeLuca. 1973. Comparative studies on the 25-hydroxylation of vitamin D₃ and dihydrotachysterol. *J. Biol. Chem.* **248**: 2974-2977.